Stockscreener 앱 받기
39.64
3.97%
-1.64
시간 외 거래:
39.64
전일 마감가:
$41.28
열려 있는:
$41.44
하루 거래량:
940.56K
Relative Volume:
1.14
시가총액:
$3.06B
수익:
$13.17M
순이익/손실:
$-199.06M
주가수익비율:
-14.47
EPS:
-2.74
순현금흐름:
$-156.53M
1주 성능:
+0.08%
1개월 성능:
+6.82%
6개월 성능:
+28.99%
1년 성능:
-1.91%
1일 변동 폭
$39.55
$41.66
1주일 범위
$38.49
$41.66
52주 변동 폭
$26.74
$46.00
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
명칭
Xenon Pharmaceuticals Inc
전화
(604) 484-3300
주소
200 - 3650 GILMORE WAY, BURNABY
XENE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
39.64 | 3.18B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-03 | 재개 | Wells Fargo | Overweight |
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-01 | 개시 | H.C. Wainwright | Buy |
| 2024-01-04 | 개시 | Citigroup | Buy |
| 2023-12-08 | 개시 | Robert W. Baird | Outperform |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-04-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-14 | 개시 | Goldman | Buy |
| 2022-12-12 | 개시 | Cowen | Outperform |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-10-19 | 개시 | Raymond James | Outperform |
| 2022-08-29 | 개시 | BofA Securities | Buy |
| 2022-07-21 | 개시 | JP Morgan | Overweight |
| 2021-10-28 | 개시 | RBC Capital Mkts | Outperform |
| 2020-10-02 | 개시 | SVB Leerink | Outperform |
| 2020-07-21 | 개시 | Needham | Buy |
| 2020-06-01 | 재개 | Jefferies | Buy |
| 2020-03-25 | 개시 | Wedbush | Outperform |
| 2020-01-08 | 개시 | William Blair | Outperform |
| 2019-09-20 | 개시 | Guggenheim | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2017-03-13 | 개시 | Jefferies | Buy |
| 2016-10-21 | 개시 | Stifel | Buy |
| 2016-09-26 | 개시 | Guggenheim | Buy |
| 2016-04-14 | 재확인 | Jefferies | Buy |
| 2015-10-30 | 재개 | Jefferies | Buy |
| 2014-12-02 | 개시 | Canaccord Genuity | Buy |
모두보기
Xenon Pharmaceuticals Inc 주식(XENE)의 최신 뉴스
Research Analysts Issue Forecasts for XENE FY2025 Earnings - MarketBeat
What is Bloom Burton’s Estimate for XENE FY2025 Earnings? - Defense World
Xenon Pharmaceuticals Issues Equity Inducement Grants to New Employees - MSN
Will Xenon Pharmaceuticals Inc. stock attract ESG investorsDay Trade & Free Weekly Watchlist of Top Performers - newser.com
Will Xenon Pharmaceuticals Inc. stock attract more institutional investorsJuly 2025 Selloffs & Verified Entry Point Detection - newser.com
Is Xenon Pharmaceuticals Inc. stock attractive for income investors2025 Trading Recap & Capital Efficiency Focused Ideas - newser.com
What analysts say about Xenon Pharmaceuticals Inc stockInsider Selling Patterns & Budget Friendly Trading Strategies - earlytimes.in
Brokers Offer Predictions for XENE FY2026 Earnings - MarketBeat
Bloom Burton Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to "Strong-Buy" - MarketBeat
Xenon Pharmaceuticals’ (XENE) Outperform Rating Reaffirmed at William Blair - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Given “Buy” Rating at Chardan Capital - Defense World
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
77,750 Options: Xenon Pharmaceuticals Grants Equity to Seven New Hires at $39.20, Oct 2, 2025 - Stock Titan
Xenon Pharmaceuticals' (XENE) Outperform Rating Reiterated at William Blair - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Receives "Buy" Rating from Chardan Capital - MarketBeat
XENE: Chardan Capital Maintains Buy Rating with $55 Price Target | XENE Stock News - GuruFocus
Chardan Capital Maintains Xenon Pharmaceuticals (XENE) Buy Recommendation - Nasdaq
Transcript : Xenon Pharmaceuticals Inc.Special Call - MarketScreener
Will Xenon Pharmaceuticals Inc. stock recover after recent dropJobs Report & Verified Swing Trading Watchlist - newser.com
Is it time to cut losses on Xenon Pharmaceuticals Inc.Market Growth Summary & Safe Capital Investment Plans - newser.com
Xenon Pharmaceuticals Inc. $XENE Shares Purchased by J. Safra Sarasin Holding AG - MarketBeat
Xenon Pharmaceuticals announces executive changes - MSN
HighMark Wealth Management LLC Has $817,000 Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Inc. stock chart pattern explainedWeekly Volume Report & Low Risk Entry Point Tips - newser.com
Will Xenon Pharmaceuticals Inc. stock maintain growth storyGap Down & Free AI Powered Buy and Sell Recommendations - newser.com
Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE) - MarketBeat
Insider Selling: Xenon Pharmaceuticals (NASDAQ:XENE) CEO Sells 25,000 Shares of Stock - MarketBeat
Xenon Pharmaceuticals Hits Day High with Strong 9.94% Intraday Surge - Markets Mojo
Published on: 2025-10-01 07:26:08 - newser.com
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
Xenon Pharmaceuticals Inc (XENE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Xenon Pharmaceuticals Inc 주식 (XENE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| MORTIMER IAN | PRESIDENT, CEO & INTERIM CFO |
Oct 01 '25 |
Sale |
40.16 |
25,000 |
1,004,000 |
31,302 |
5.74%
자본화:
|
볼륨(24시간):